CTLA4 and neoplasm: Similarly, E7046, an orally bioavailable EP4-specific antagonist, also showed synergistic antitumor activity when combined with anti-CTLA-4 antibodies through impairing tumor-promoting MDSCs differentiation, M2 macrophage polarization, and Tregs-derived immunosuppression (98).